Last reviewed · How we verify

Corvert (Ibutilide)

Medical University of Vienna · FDA-approved active Small molecule

Ibutilide is a Class III antiarrhythmic agent that prolongs the cardiac action potential duration by blocking potassium channels and activating inward sodium current.

Ibutilide is a Class III antiarrhythmic agent that prolongs the cardiac action potential duration by blocking potassium channels and activating inward sodium current. Used for Acute conversion of atrial fibrillation or atrial flutter to normal sinus rhythm.

At a glance

Generic nameCorvert (Ibutilide)
SponsorMedical University of Vienna
Drug classClass III antiarrhythmic agent
TargetDelayed rectifier potassium channels (hERG); sodium channels
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Ibutilide works primarily through delayed rectifier potassium channel blockade, which extends the refractory period of cardiac tissue. Additionally, it enhances the inward sodium current during the action potential plateau phase. These combined effects increase the duration of the action potential and refractory period, helping to terminate atrial arrhythmias by increasing the likelihood of successful electrical cardioversion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: